ReviewDeutsches Arzteblatt international2017
Treatment Options for Gout.
Review in Deutsches Arzteblatt international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 85 citations in OpenAlex.
- Effect of vitamin C and hesperidin on serum uric acid concentrations in healthy adults with high uric acid levels: the randomized controlled 'HesperidrinC trial'.European journal of nutrition · 2026Trial
- Determinants of gout therapy non-adherence in patients attending an Egyptian rheumatology outpatient clinic.BMC nursing · 2026Article
- Article
- Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Elevated serum cystatin C predicts tophus formation in gout: evidence from a cross-sectional study.Frontiers in endocrinology · 2026Article
- Urine Metabolomics of Gout Reveals the Dynamic Reprogramming and Non-Invasive Biomarkers of Disease Progression.Metabolites · 2025Article
- Integrating natural products with modern medicine in the treatment of gouty arthritis: a review.Inflammopharmacology · 2025Review
- Gouty Arthritis Treatment: Advancements in Topical Lipid-Based Nanocarrier Delivery Systems.Advanced pharmaceutical bulletin · 2025Review
- The dual regulatory effects of intestinal microorganisms and their metabolites in gouty arthritis pathogenesis: a balance between promotion and inhibition.Frontiers in immunology · 2025Review
- Exercise and hyperuricemia: an opinion article.Annals of medicine · 2024Article
- Advances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions.International journal of molecular sciences · 2024Review
- Mechanism of flavonoids in the treatment of gouty arthritis (Review).Molecular medicine reports · 2024Review
- Review
- Hospital Length of Stay and Associated Factors in Patients with Osteoarthritis from Germany: A Cross-Sectional Study.Journal of clinical medicine · 2024Article
- Effects of evodiamine on ROS/TXNIP/NLRP3 pathway against gouty arthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Formulation Development of Fast Dissolving Microneedles Loaded with Cubosomes of Febuxostat: In Vitro and In Vivo Evaluation.Pharmaceutics · 2023Article
- Association between smoking behavior and serum uric acid among the adults: Findings from a national cross-sectional study.PloS one · 2023Article
- Anti-inflammation is an important way that Qingre-Huazhuo-Jiangsuan recipe treats acute gouty arthritis.Frontiers in pharmacology · 2023Article
- Musculoskeletal complications in patients with diabetes mellitus.The Korean journal of internal medicine · 2022Review
- Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.The Journal of veterinary medical science · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background1-2% of adults in Germany suffer from gout. Gout is one of the few rheumatological diseases that can be cured. It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia. Painful redness and swelling of the affected joints are typical findings. Multiple pertinent guidelines and treatment recommendations have been published, but there is reason to believe that patients with gout are not always treated accordingly.
methodsThis review is based on relevant publications from the years 2000-2016 that were retrieved by a selective search in the Cochrane and PubMed databases.
resultsIn a person with normal renal function, asymptomatic hyperuricemia is not an indication for treatment to lower the serum uric acid level. The drugs of first choice for acute gouty arthritis are nonsteroidal antiinflammatory drugs (NSAID), corticosteroids, and colchicine. Treatment with xanthine oxidase inhibitors (XOI) or uricosuric drugs is indicated for patients with a recurrent or severe course; the target uric acid value is <6 mg/dL. Long-term treatment should be initiated only after resolution of the acute attack. For patients with refractory gout, lesinurad (approved in February 2016) in combination with XOI is a new treatment option that can be considered. Comprehensive patient education and counseling is an important component of the treatment of patients with gout. Regular laboratory follow-up is necessary as well.
conclusionThe prevalence of gout is rising around the world. Patients with gout could benefit greatly from consistent implementation of the existing treatment guidelines and recommendations. In the future, controlled trials should be conducted to determine the best time to start treatment and the optimal target level for the serum uric acid concentration in terms of a risk/benefit analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.